Short Interest in Heart Test Laboratories, Inc. (NASDAQ:HSCS) Rises By 343.2%

Heart Test Laboratories, Inc. (NASDAQ:HSCS) was the recipient of a significant increase in short interest in the month of April. As of April 15th, there was short interest totalling 599,600 shares, an increase of 343.2% from the March 31st total of 135,300 shares. Currently, 1.1% of the company’s stock are short sold. Based on an average daily trading volume, of 1,920,000 shares, the short-interest ratio is currently 0.3 days.

Heart Test Laboratories Stock Performance

Shares of Heart Test Laboratories stock remained flat at $0.10 during trading on Friday. The stock had a trading volume of 1,613,118 shares, compared to its average volume of 2,779,883. The stock has a market cap of $6.39 million, a price-to-earnings ratio of -0.20 and a beta of 3.44. Heart Test Laboratories has a 1 year low of $0.09 and a 1 year high of $1.32. The firm’s 50-day moving average is $0.12 and its two-hundred day moving average is $0.17.

Heart Test Laboratories (NASDAQ:HSCS) last announced its quarterly earnings results on Thursday, March 14th. The company reported ($0.03) EPS for the quarter. The firm had revenue of $0.02 million during the quarter.

Hedge Funds Weigh In On Heart Test Laboratories

A hedge fund recently raised its stake in Heart Test Laboratories stock. Astoria Strategic Wealth Inc. raised its stake in Heart Test Laboratories, Inc. (NASDAQ:HSCS) by 246.1% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 81,995 shares of the company’s stock after purchasing an additional 58,303 shares during the period. Astoria Strategic Wealth Inc. owned 0.75% of Heart Test Laboratories worth $35,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors own 17.24% of the company’s stock.

About Heart Test Laboratories

Heart Test Laboratories, Inc, a medical technology company, provides cardiovascular diagnostic devices. The company offers MyoVista wavECG, a resting 12-lead electrocardiograph (ECG) to provide diagnostic information related to cardiac dysfunction, as well as conventional ECG information. It serves clinics, doctor's offices, urgent care centers, and hospitals.